November was a banner month for medical market consolidation, with Philips/ADAC, Cerner/ADAC, Philips/Agilent, Kodak/Lumisys, and Kodak/R2 among the more prominent deals. Now Cardiac Science has offered to buy Spacelabs Medical for about $143
November was a banner month for medical market consolidation, with Philips/ADAC, Cerner/ADAC, Philips/Agilent, Kodak/Lumisys, and Kodak/R2 among the more prominent deals. Now Cardiac Science has offered to buy Spacelabs Medical for about $143 million, paying $15 per share for all outstanding common stock, a 45% premium over the Nov. 13 per-share price.
Spacelabs rebuffed an offer made by Cardiac Science in mid-November, prompting Cardiac Science to publish its offer openly. The company has already acquired 320,200 shares of Spacelabs and has nominated a full slate of alternate candidates for the Spacelabs board of directors.
Cardiac Science plans to integrate its automatic defibrillation technology into Spacelabs' installed base of approximately 65,000 hospital patient monitors, according to Raymond Cohen, the company's president and CEO. Cardiac wants to accelerate the adoption of its core technology by other players in the cardiac patient monitoring market, including Philips (through its acquisition of Agilent Healthcare Solutions Group), GE Medical, Siemens, and Datex Ohmeda, by exploiting Spacelabs' customer base and its cardiac telemetry and telemedicine monitoring products.
© 2000 Miller Freeman Inc.
12/13/00, Issue # 118, page 3.
ASCO: Study Reveals Significant Racial/Ethnic Disparities with PSMA PET Use for Patients with mPCa
May 30th 2025Latinx patients with metastatic prostate cancer were 63 percent less likely than non-Hispanic White patients to have PSMA PET scans, according to a study of 550 patients presented at the American Society of Clinical Oncology (ASCO) conference.
Lunit Unveils Enhanced AI-Powered CXR Software Update
May 28th 2025The Lunit Insight CXR4 update reportedly offers new features such as current-prior comparison of chest X-rays (CXRs), acute bone fracture detection and a 99.5 percent negative predictive value (NPV) for identifying normal CXRs.
New MRI Study Questions Use of Corticosteroid Injections for Knee OA
May 27th 2025Two years after intraarticular knee injections for knee osteoarthritis (OA), study participants who had corticosteroid knee injections had greater OA progression than control patients while the use of hyaluronic acid injections was associated with less OA progression.